Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human EPOR /Erythropoietin Receptor, 1mg  

Recombinant human EPOR /Erythropoietin Receptor, 1mg

Recombinant Human EPOR /Erythropoietin Receptor Protein, With C-Fc Tag (rhEPOR-Fc) Ala 25 - Cys 241 was produced in human 293 cells (HEK293).

Synonym
recombinant, human protein EPOR, Erythropoietin Receptor

More details

EPR-H5253-1K

Availability: within 7 days

1 600,00 €

Background
Erythropoietin (EPO) is the major glycoprotein hormone regulator of mammalian erythropoiesis , and is produced by kidney and liver in an oxygen-dependent manner. The biological effects of EPO are mediated by the specific erythropoietin receptor (EPOR) on bone marrow erythroblasts, which transmits signals important for both proliferation and differentiation along the erythroid lineage. EPOR is a type 1 single-transmembrane cytokine receptor, and belongs to the homodimerizing subclass which functions as ligand-induced or ligand-stabilized homodimers. EPOR pre-exists as dimers[1] which upon binding of a 34 kDa ligand erythropoietin (Epo), changes its homodimerized state. These conformational changes result in the autophosphorylation of Jak2 kinases that are pre-associated with the receptor.[2-3] Erythropoietin is necessary to maintain endothelial cells and to promote tumor angiogenesis, hence the dysregulation of EpoR may affect the growth of certain tumors.[4] EpoR signaling prevents neuronal death[5] and ischemic injury.[6]

Source
Recombinant Human EPOR /Erythropoietin Receptor Protein, With C-Fc Tag (rhEPOR-Fc) Ala 25 - Cys 241 (Accession # AAI12154) was produced in human 293 cells (HEK293).

Molecular Characterization
rhEPOR-Fc, fused with Fc fragment of human IgG1 at the C-terminus, has a calculated MW of 50.1 kDa. The predicted N-terminus is Ala 25. DTT-reduced Protein migrates as 55-60 kDa due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhEPOR-Fc by the LAL method.

Purity
>92% purity as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM tris, 100 mM glycine, pH7.0. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Measured by its binding ability in a functional ELISA. Immobilized Human EPO, Tag Free (Catalog # EPO-H4214) at 10μg/mL (100 μL/well) can bind Human EPO R, Fc Tag (Catalog # EPR-H5253) with a linear range of 0.013-0.12 μg/mL.

References

(1) Livnah O, et al., 1999, Science 283 (5404): 987–90.
(2) Youssoufian H, et al., 1993, Blood 81 (9): 2223–36.
(3) Wilson IA, Jolliffe LK., 1999, Curr. Opin. Struct. Biol. 9 (6): 696–704.
(4) Jelkmann W, et al., 2008, Crit. Rev. Oncol. Hematol. 67 (1): 39–61.
(5) Morishita E, et al., 1997, Neuroscience 76 (1): 105–16.
(6) Wright GL, et al., 2004, FASEB J. 18 (9): 1031–3.